Compass Therapeutics (CMPX) Liabilities and Shareholders Equity (2018 - 2026)

Compass Therapeutics (CMPX) has 9 years of Liabilities and Shareholders Equity data on file, last reported at $205.2 million in Q1 2026.

• For the quarter ending Q1 2026, Liabilities and Shareholders Equity rose 56.08% year-over-year to $205.2 million; the trailing twelve-month figure through Mar 2026 stood at $772.7 million (up 34.01% YoY), and the FY2025 full-year result was $219.6 million, up 56.4% from the prior year.
• Liabilities and Shareholders Equity fell to $205.2 million in Q1 2026, from $219.6 million in the prior quarter.
• In the past five years, Liabilities and Shareholders Equity ranged from a high of $231.3 million in Q3 2025 to a low of $116.7 million in Q2 2025.
• A 5-year average of $165.8 million and a median of $156.9 million in 2023 frame the typical range for Liabilities and Shareholders Equity.
• Across the five-year window, Liabilities and Shareholders Equity soared 266.31% in 2022 and fell 25.01% in 2025, its largest moves.
• Tracing CMPX's Liabilities and Shareholders Equity over 5 years: stood at $199.6 million in 2022, then fell by 21.42% to $156.9 million in 2023, then declined by 10.5% to $140.4 million in 2024, then surged by 56.4% to $219.6 million in 2025, then slipped by 6.57% to $205.2 million in 2026.
• Business Quant data shows CMPX's Liabilities and Shareholders Equity at $205.2 million in Q1 2026, $219.6 million in Q4 2025, and $231.3 million in Q3 2025.